Share This Article:

Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab

Abstract Full-Text HTML XML Download Download as PDF (Size:281KB) PP. 833-840
DOI: 10.4236/jct.2015.610091    2,775 Downloads   3,278 Views   Citations

ABSTRACT

Background: To describe healthcare costs, excluding ipilimumab drug costs, in patients with advanced melanoma receiving ipilimumab in the US community practice setting. Methods: This was a retrospective chart review of unresectable stage III/IV melanoma patients who received first-line ipilimumab monotherapy between 04/2011 and 09/2012. Healthcare resource utilization included inpatient, emergency, specialist and hospice visits, laboratory tests, radiation, surgeries, and nursing home stays. Publicly available US unit costs were applied to each resource type to estimate costs, which were analyzed by time periods: during ipilimumab treatment, post-ipilimumab treatment (post-regimen), and within 90 days prior to death (pre-death). Generalized linear mixed models were used to explore cost predictors during the treatment period, on a per-dose-interval basis, defined as the time between ipilimumab doses. Results: Data were abstracted from 273 patient charts at 34 sites. Excluding ipilimumab drug costs, total monthly costs during the treatment regimen, post-regimen, and pre-death periods were $690, $2151, and $5123, respectively. Total healthcare costs were 27 times higher during dose intervals with a grade 3/4 adverse event compared with intervals without a grade 3/4 adverse event. Eastern Cooperative Oncology Group performance status ≥ 2 (vs 0) was also associated with significantly higher cost per dose interval. Conclusions: In this population, monthly costs exclusive of drug were significantly lower during the treatment period than in subsequent periods. Unfavorable ECOG PS was associated with significant increases in cost per dose interval. Grade 3/4 adverse events were associated with a marked increase in healthcare costs, but occurred in a small proportion of dose intervals.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Tarhini, A. , Corman, S. , Rao, S. , Margolin, K. , Ji, X. , Mehta, S. and Botteman, M. (2015) Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab. Journal of Cancer Therapy, 6, 833-840. doi: 10.4236/jct.2015.610091.

References

[1] Linos, E., Swetter, S.M., Cockburn, M.G., Colditz, G.A. and Clarke, C.A. (2009) Increasing Burden of Melanoma in the United States. Journal of Investigative Dermatology, 129, 1666-1674.
http://dx.doi.org/10.1038/jid.2008.423
[2] Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29.
http://dx.doi.org/10.3322/caac.21254
[3] Balsh, C.M., Gershenwald, J.E., Soong, S.-J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. (2009) Final Version of the 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology, 27, 6199-6206.
http://dx.doi.org/10.1200/JCO.2009.23.4799
[4] Ilieva, K.M., Correa, I., Josephs, D.H., Karagiannis P., Egbuniwe, I.U., Cafferkey, M.I., et al. (2014) Effects of BRAF Mutations and BRAF Inhibition on Immune Responses in Melanoma. Molecular Cancer Therapeutics, 3, 2769-2783.
[5] Mervic, L. (2012) Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women. PLoS One, 7, e32955.
http://dx.doi.org/10.1371/journal.pone.0032955
[6] Korn, E.L., Liu, P.Y., Lee, S.J., Chapman, J.-A., Niedzwiecki, D., Suman, V.J., et al. (2008) Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. Journal of Clinical Oncology, 26, 527-534.
http://dx.doi.org/10.1200/JCO.2007.12.7837
[7] Manola, J., Atkins, M., Ibrahim, J. and Kirkwood, J. (2000). Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials. Journal of Clinical Oncology, 18, 3782-3793.
[8] Hodi, F.S., O’Day, S.J., McDermott, D.V., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363, 711-723.
http://dx.doi.org/10.1056/NEJMoa1003466
[9] Robert, C., Karaszewska, B., Shachter, J, Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. (2015) Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. New England Journal of Medicine, 372, 30-39.
http://dx.doi.org/10.1056/NEJMoa1412690
[10] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K. and Hamid, O. (2015) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 10, 1889-1894.
http://dx.doi.org/10.1200/JCO.2014.56.2736
[11] Margolin, K.A., Tarhini, A., Rao, S., Katyal, M., Chang, I.-F., Johnson D.B., et al. (2015) Effectiveness and Safety of Ipilimumab Therapy in Melanoma: Evidence from a US Multisite Observational Chart Review. Journal of Community and Supportive Oncology, 13, 131-138.
http://dx.doi.org/10.12788/jcso.0124
[12] Guy, G.P., Ekwueme, D.U., Tangka, F.K. and Richardson, L.C. (2012) Melanoma Treatment Costs: A Systematic Review of the Literature, 1990-2011. American Journal of Preventive Medicine, 43, 537-545.
http://dx.doi.org/10.1016/j.amepre.2012.07.031
[13] Tsao, H., Rogers, G.S. and Sober, A.J. (1998) An Estimate of the Annual Direct Cost of Treating Cutaneous Melanoma. Journal of the American Academy of Dermatologists, 38, 669-680.
http://dx.doi.org/10.1016/S0190-9622(98)70195-1
[14] Housman, T.S., Feldman, S.R., Williford, P.M., Fleischer Jr., A.B., Goldman, N.D., Acostamadiedo, J.M., et al. (2003) Skin Cancer Is among the Most Costly of all Cancers to Treat in a Medicare Population. Journal of the American Academy of Dermatologists, 48, 425-429.
http://dx.doi.org/10.1067/mjd.2003.186
[15] Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS.
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
[16] Ingenix (2011) National Fee Analyzer. Ingenix, Eden Prairie.
[17] Healthcare Cost and Utilization Project (2012) Overview of the National (Nationwide) Inpatient Sample (NIS). Agency for Healthcare Research and Quality, Rockville.
http://www.hcup-us.ahrq.gov/nisoverview.jsp
[18] Davis, K.L., Mitra, D., Kotapati, S., Ibrahim, R. and Wolchok, J.D. (2009) Direct Economic Burden of High-Risk and Metastatic Melanoma in the Elderly: Evidence from the SEER-Medicare Linked Database. Applied Health Economics and Health Policy, 7, 31-41.
http://dx.doi.org/10.1007/BF03256140
[19] Centers for Medicare & Medicaid Services (2014) ASP Drug Pricing Files, April 2014 Update.
http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/Apr-14-ASP-Pricing-File.zip
[20] Red Book Online. Truven Health Analytics, Inc., Greenwood Village. (Updated Periodically)
http://www.micromedexsolutions.com
[21] US Bureau of Labor Statistics (2014) Consumer Price Index; Medical Component.
http://www.bls.gov/CPI
[22] Reyes, C., DaCosta Byfield, S., Linke, R., Satram-Hoang, S. and Teitelbaum, A.H. (2013) The Burden of Metastatic Melanoma: Treatment Patterns, Healthcare Use (Utilization), and Costs. Melanoma Research, 23, 159-166.
http://dx.doi.org/10.1097/CMR.0b013e32835e58d6
[23] Oster, G., Taneja, C., Penrod, J.R., Yang, A.S. and Edelsberg, J. (2011) Economic Burden of Advanced Melanoma: Findings from a Large US Health Insurance Database. Value in Health, 14, A507.
http://dx.doi.org/10.1016/j.jval.2011.08.1493
[24] Hillner, B.E., Kirkwood, J.M. and Agarwala, S.S. (2001) Burden of Illness Associated with Metastatic Melanoma: An Audit of 100 Consecutive Referral Center Cases. Cancer, 91, 1814-1821.
http://dx.doi.org/10.1002/1097-0142(20010501)91:9<1814::AID-CNCR1201>3.0.CO;2-W
[25] Macahilig, C.P., Botteman, M., Prinz, J.M., Yang, A.S. and Penrod, J.R. (2011) Patterns of Care and Healthcare Utilization of US Advanced Melanoma Patients: Evidence from a Medical Chart Review. Poster Presented at Perspectives in Melanoma XV, New York, 16-17 September 2011.
[26] Weber, J.S., Minor, D.R., D’Angelo, S.P., Hodi, F.S., Gutzmer, R. and Neyns, B. (2014) A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) versus Investigator’s Choice Chemotherapy (ICC) in Patients with Advanced Melanoma after Prior Anti-CTLA-4 Therapy. Proceedings of the European Society for Medical Oncology Congress, Madrid, 26-30 September 2014.
[27] Yabroff, K.R., Lamont, E.B., Mariotto, A., Warren, J.L., Topor, M., Meekins, A., et al. (2008) Cost of Care for Elderly Cancer Patients in the United States. Journal of the National Cancer Institute, 100, 630-641.
http://dx.doi.org/10.1093/jnci/djn103
[28] Mariotto, A.B., Yabroff, K.R., Shao, Y., Feuer, E.J. and Brown, M.L. (2011) Projections of the Cost of Cancer Care in the United States: 2010-2020. Journal of the National Cancer Institute, 103, 117-128.
http://dx.doi.org/10.1093/jnci/djq495

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.